Exelixis (NASDAQ: EXEL) and Iqvia (NYSE:IQV) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, analyst recommendations, institutional ownership and earnings.
This is a summary of recent recommendations and price targets for Exelixis and Iqvia, as provided by MarketBeat.com.
||Strong Buy Ratings
Exelixis presently has a consensus target price of $34.00, suggesting a potential upside of 61.53%. Iqvia has a consensus target price of $110.38, suggesting a potential upside of 12.70%. Given Exelixis’ stronger consensus rating and higher probable upside, equities research analysts plainly believe Exelixis is more favorable than Iqvia.
This table compares Exelixis and Iqvia’s net margins, return on equity and return on assets.
||Return on Equity
||Return on Assets
Valuation & Earnings
This table compares Exelixis and Iqvia’s revenue, earnings per share (EPS) and valuation.
||Earnings Per Share
Iqvia has higher revenue and earnings than Exelixis. Iqvia is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks.
Institutional and Insider Ownership
80.5% of Exelixis shares are held by institutional investors. Comparatively, 92.4% of Iqvia shares are held by institutional investors. 5.1% of Exelixis shares are held by insiders. Comparatively, 6.0% of Iqvia shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Risk & Volatility
Exelixis has a beta of 2.1, suggesting that its share price is 110% more volatile than the S&P 500. Comparatively, Iqvia has a beta of 0.63, suggesting that its share price is 37% less volatile than the S&P 500.
Exelixis beats Iqvia on 8 of the 14 factors compared between the two stocks.
Exelixis Company Profile
Exelixis, Inc. is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company’s cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors. The Company’s CABOMETYX tablets are approved for previously treated advanced kidney cancer and COMETRIQ capsules are approved for progressive, metastatic medullary thyroid cancer. The third product, Cotellic, is a formulation of cobimetinib, a selective inhibitor of MEK is approved as part of a combination regimen to treat advanced melanoma. Both cabozantinib and cobimetinib have shown potential in a range of forms of cancer and are the subjects of broad clinical development programs. The Company’s XL888 is a small molecule oral inhibitor of Heat Shock Protein 90 (HSP90), a molecular chaperone protein.
Iqvia Company Profile
IQVIA Holdings Inc., formerly Quintiles IMS Holdings, Inc., provides integrated information and technology-enabled healthcare services. The Company operates through segments, including Commercial Solutions; Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offerings include national information offerings, sub-national information offerings, technology solutions, and workflow analytics and consulting services. The Research & Development Solutions segment provides biopharmaceutical development services. It offers project management and clinical monitoring, clinical trial support services, Q2 solutions, and strategic planning and design. The Integrated Engagement Services segment offerings include healthcare provider engagement services, patient engagement services, and scientific strategy and medical affairs services. The Company has its operations in the Americas, Europe and Africa, and the Asia-Pacific.
Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.